MKI67 and neoplasm: In the multivariate analysis, which adjusted for Ki-67 expression, sex, time of progression, age, and tumor size, chronic treatment with somatostatin analogues was found to be independently associated with a lower number of recurrences (OR 0.054, p = 0.005) (Figure 3).